个人简介

Angela gained her MChem degree from the University of Oxford in 2000 and her DPhil in Organic Chemistry in 2004 under the joint supervision of Professor Steve Davies and Dr Tim Perera from Yamanouchi plc (now Astellas Pharma Inc.). The main focus of her work was using a pharmacophore modelling approach for the development of novel phosphatase inhibitors but also encompassed the development of novel asymmetric synthesis methodologies and the synthesis of molecules of biological importance. In July 2007 she was awarded a prestigious Research Councils’ UK Fellowship in Medicinal Chemistry jointly between the Departments of Chemistry and Pharmacology in Oxford. In 2012 she was appointed as University Lecturer, and in 2014 an Associate Professor in Medicinal Chemistry.

研究领域

Development of small molecule utrophin modulators for the treatment of Duchenne Muscular Dystrophy Development of small molecules to manipulate stem and progenitor cell fate in vitro and in vivo. Cancer medicinal chemistry: chemical probes for tumour biomarker detection, epigenetic cancer targets, new anti-tumour agents. Development of small molecule modulators to study developmental signalling pathways, e.g. Hedgehog, Wnt/wingless, FGF and Bone Morphogenetic Protein.

Angela’s research interests are in the field of medicinal chemistry and broadly encompass the development of small molecules to control signalling processes. Angela has realised several successful multidisciplinary research collaborations, including identifying small molecules to upregulate utrophin for the treatment of Duchenne Muscular Dystrophy, developing novel inhibitors and activators of developmental signalling pathways and new anti-cancer agents and cancer biomarker detection methods. Since 2005 Angela has initiated a number of collaborative programmes involving the discovery and development of small molecules to manipulate stem cell fate.

近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Guiraud, S, Squire, SE, Edwards, B, Chen, H, Burns, DT, Shah, N, Babbs, A, Davies, SG, Wynne, GM, Russell, AJ, Elsey, D, Wilson, FX, Tinsley, JM, and Davies, KE (2015) Second-generation compound for the modulation of utrophin in the therapy of DMD. Taylor, L, Christou, I, Kapellos, TS, Buchan, A, Brodermann, MH, Gianella-Borradori, M, Russell, A, Igbal, AJ, and Greaves, DR (2015) Primary macrophage chemotaxis induced by cannabinoid receptor 2 agonists occurs independently of the CB2 receptor Davies, SG, Kennewell, PD, Russell, AJ, Seden, PT, Westwood, R, and Wynne, GM (2015) Stemistry: the control of stem cells in situ using chemistry. Gianella-Borradori, M, Christou, I, Bataille, CJR, Cross, RL, Wynne, GM, Greaves, DR, and Russell, AJ (2015) Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists. Egleton, JE, Thinnes, CC, Seden, PT, Laurieri, N, Lee, SP, Hadavizadeh, KS, Measures, AR, Jones, AM, Thompson, S, Varney, A, Wynne, GM, Ryan, A, Sim, E, and Russell, AJ (2014) Structure-activity relationships and colorimetric properties of specific probes for the putative cancer biomarker human arylamine N-acetyltransferase 1. Lufino, MMP, Silva, AM, Nemeth, AH, Alegre-Abarrategui, J, Russell, AJ, and Wade-Martins, R (2013) A GAA repeat expansion reporter model of Friedreich's ataxia recapitulates the genomic context and allows rapid screening of therapeutic compounds.